Simba Gill - Jun 8, 2023 Form 4 Insider Report for Evelo Biosciences, Inc. (EVLO)

Role
President & CEO, Director
Signature
/s/ Marella Thorell, Attorney-in-Fact for Balkrishan (Simba) Gill, Ph.D.
Stock symbol
EVLO
Transactions as of
Jun 8, 2023
Transactions value $
$0
Form type
4
Date filed
6/12/2023, 04:01 PM
Previous filing
May 10, 2023
Next filing
Jun 22, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Stock Option (Right to Buy) Award $0 +1M $0.00 1M Jun 8, 2023 Common Stock 1M $0.97 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Om March 17, 2023, the reporting person was granted an option to purchase 1,000,000 shares of the issuer's common stock subject to certain conditions, including the approval of the amendment and restatement of the Evelo Biosciences, Inc. 2018 Incentive Award Plan (the "2018 Plan") by stockholders at the issuer's 2023 Annual Meeting of Stockholders. The stockholders approved the amendment and restatement of the 2018 Plan on June 8, 2023.
F2 The option vests in forty-eight (48) substantially equal installments at the end of each monthly anniversary of February 7, 2023, subject to the reporting person's continued service to the issuer on each such vesting date.

Remarks:

Exhibit 24: Power of Attorney